High-density lipoprotein cholesterol and triglycerides in the statin era: A pending issue?

被引：0
作者：
Paillard, Francois [1 ]
机构：
[1] CHU Pontchaillou, Dept Cardiol, Ctr Prevent Vasc & Consultat Facteurs Risque, F-35033 Rennes 9, France
来源：
ARCHIVES OF CARDIOVASCULAR DISEASES | 2009年 / 102卷 / 03期
关键词：
HDL-Cholesterol; Triglycerides; Statins; Metabolic syndrome; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; HIGH-RISK; PREVENTION; GEMFIBROZIL; ASSOCIATION; EVENTS; TRIAL; ACID; MEN;
D O I：
10.1016/j.acvd.2008.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：165 / 167
页数：3
相关论文
共 23 条
  • [1] HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Barter, Philip
    Gotto, Antonio M.
    LaRosa, John C.
    Maroni, Jaman
    Szarek, Michael
    Grundy, Scott M.
    Kastelein, John J. P.
    Bittner, Vera
    Fruchart, Jean-Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) : 1301 - 1310
  • [2] Effects of torcetrapib in patients at high risk for coronary events
    Barter, Philip J.
    Caulfield, Mark
    Eriksson, Mats
    Grundy, Scott M.
    Kastelein, John J. P.
    Komajda, Michel
    Lopez-Sendon, Jose
    Mosca, Lori
    Tardif, Jean-Claude
    Waters, David D.
    Shear, Charles L.
    Revkin, James H.
    Buhr, Kevin A.
    Fisher, Marian R.
    Tall, Alan R.
    Brewer, Bryan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
  • [3] Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials
    Brown, B. Greg
    Stukovsky, Karen Hinckley
    Zhao, Xue-Qiao
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (06) : 631 - 636
  • [4] 15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN
    CANNER, PL
    BERGE, KG
    WENGER, NK
    STAMLER, J
    FRIEDMAN, L
    PRINEAS, RJ
    FRIEDEWALD, W
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) : 1245 - 1255
  • [5] Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans
    Cheng, K
    Wu, TJ
    Wu, KK
    Sturino, C
    Metters, K
    Gottesdiener, K
    Wright, SD
    Wang, ZY
    O'Neill, G
    Lai, E
    Waters, MG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (17) : 6682 - 6687
  • [6] Apolipoprotein A-IMilano:: current perspectives
    Chiesa, G
    Sirtori, CR
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2003, 14 (02) : 159 - 163
  • [7] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [8] Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Deedwania, Prakash
    Barter, Philip
    Carmena, Rafael
    Fruchart, Jean-Charles
    Grundy, Scott M.
    Haffner, Steven
    Kastelein, John J. P.
    LaRosa, John C.
    Schachner, Holly
    Shepherd, James
    Waters, David D.
    [J]. LANCET, 2006, 368 (9539) : 919 - 928
  • [9] Beyond high-density lipoprotein cholesterol levels - Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches
    deGoma, Emil M.
    deGoma, Rolando L.
    Rader, Daniel J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (23) : 2199 - 2211
  • [10] Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol
    deGoma, Emil M.
    Leeper, Nicholas J.
    Heidenreich, Paul A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 49 - 55
123